Rotavirus vaccines: progress and new developments

References

• Uhnoo I, Olding-Stenkvist E, Kreuger A. Clinical features of acute gastroenteritis associated with rotavirus, enteric adenoviruses, and bacteria. Arch Dis Child. 1986;61(8):732–738.
   PubMed Web of Science ®Google Scholar
• GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602
   Google Scholar
• Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565–572.
   PubMed Web of Science ®Google Scholar
• Rotavirus vaccines WHO position paper. 2013 - Recommendations. Vaccine. 2013 January;31(52):6170–6171.
   PubMedGoogle Scholar
• Tate JE, Burton AH, Boschi-Pinto C, et al. National Estimates of Rotavirus Mortality in Children <5 years of age, 2000-2013. Clin Infect Dis. 2016;62(Suppl 2):S96–s105.
   PubMed Web of Science ®Google Scholar
• Troeger C, Khalil IA, Rao PC, et al. Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years. JAMA Pediatr. 2018;172(10):958–965.
   PubMed Web of Science ®Google Scholar
• Burke RM, Tate JE, Kirkwood CD, et al. Current and new rotavirus vaccines. Curr Opin Infect Dis. 2019;32(5):435–444.
   PubMed Web of Science ®Google Scholar
• International Vaccine Access Center (IVAC). Available at: www.view-hub.org. Accessed 5/6/2021.
   Google Scholar
• Nair NP, Reddy NS, Giri S, et al. Rotavirus vaccine impact assessment surveillance in India: protocol and methods. BMJ Open. 2019;9(4):e024840.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2020 – conclusions and recommendations. Releve epidemiologique hebdomadaire. 2020;95(48):585–608.
   Google Scholar
• Aliabadi N, Wikswo ME, Tate JE, et al. Factors Associated With Rotavirus Vaccine Coverage. Pediatrics. 2019;143(2):e20181824.
   PubMed Web of Science ®Google Scholar
• Derso T, Kebede A, Wolde HF, et al. Rotavirus Vaccine Coverage and Associated Factors Among a Rural Population: findings from a Primary Health-Care Project in Two Northwest Ethiopia Districts. Pediatric Health Med Ther. 2020;11:429–435.
   PubMed Web of Science ®Google Scholar
• Wilson SE, Chung H, Schwartz KL, et al. Rotavirus vaccine coverage and factors associated with uptake using linked data: ontario, Canada. PloS One. 2018;13(2):e0192809.
   PubMed Web of Science ®Google Scholar
• Wandera EA, Mohammad S, Ouko JO, et al. Variation in rotavirus vaccine coverage by sub-counties in Kenya. Trop Med Health. 2017;45:9.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Update of a systematic review and meta-analysis of the safety, effectiveness and efficacy of childhood schedules using Rotavirus vaccines Cochrane Response. 2021.
   Google Scholar
• Burnett E, Parashar UD, Tate JE. Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis. Lancet Glob Health. 2020;8(9):e1195–e202.
   PubMed Web of Science ®Google Scholar
• Murunga N, Po G, Maia M,CNA. Effectiveness of Rotarix (®) vaccine in Africa in the first decade of progressive introduction, 2009–2019: systematic review and meta-analysis. Wellcome Open Res. 2020;5:187.
   Google Scholar
• Wang Y, Li J, Dai P, et al. Effectiveness of the oral human attenuated pentavalent rotavirus vaccine (RotaTeq™) postlicensure: a meta-analysis-2006-2020. Expert Rev Vaccines. 2021;20(4):437–448.
   PubMed Web of Science ®Google Scholar
• Velasquez DE, Parashar U, Jiang B. Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors. Expert Rev Vaccines. 2018;17(2):145–161.
   PubMed Web of Science ®Google Scholar
• Desselberger U. Differences of Rotavirus Vaccine Effectiveness by Country: likely Causes and Contributing Factors. Pathogens. 2017;6:4.
   Web of Science ®Google Scholar
• Parker EP, Ramani S, Lopman BA, et al. Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol. 2018;13(1):97–118.
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Glass R, Singh S, et al. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine. 2014;32(6):651–656.
   PubMed Web of Science ®Google Scholar
• Becker-Dreps S, Vilchez S, Velasquez D, et al. Rotavirus-specific IgG antibodies from mothers’ serum may inhibit infant immune responses to the pentavalent rotavirus vaccine. Pediatr Infect Dis J. 2015;34(1):115–116.
   PubMed Web of Science ®Google Scholar
• Moon SS, Groome MJ, Velasquez DE, et al. Prevaccination Rotavirus Serum IgG and IgA Are Associated With Lower Immunogenicity of Live, Oral Human Rotavirus Vaccine in South African Infants. Clin Infect Dis. 2016;62(2):157–165.
   PubMed Web of Science ®Google Scholar
• Rongsen-Chandola T, Strand TA, Goyal N, et al. Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. Vaccine. 2014;32(Suppl 1):A134–9.
   PubMed Web of Science ®Google Scholar
• Groome MJ, Moon SS, Velasquez D, et al. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ. 2014;92(4):238–245.
   PubMed Web of Science ®Google Scholar
• Colgate ER, Haque R, Dickson DM, et al. Delayed Dosing of Oral Rotavirus Vaccine Demonstrates Decreased Risk of Rotavirus Gastroenteritis Associated With Serum Zinc: a Randomized Controlled Trial. Clin Infect Dis. 2016;63(5):634–641.
   PubMed Web of Science ®Google Scholar
• Chattha KS, Kandasamy S, Vlasova AN, et al. Vitamin A deficiency impairs adaptive B and T cell responses to a prototype monovalent attenuated human rotavirus vaccine and virulent human rotavirus challenge in a gnotobiotic piglet model. PloS One. 2013;8(12):e82966.
   PubMed Web of Science ®Google Scholar
• Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8(9):685–698.
   PubMed Web of Science ®Google Scholar
• Iturriza-Gómara M, Cunliffe NA. The Gut Microbiome as Possible Key to Understanding and Improving Rotavirus Vaccine Performance in High-Disease Burden Settings. J Infect Dis. 2017;215(1):8–10.
   PubMed Web of Science ®Google Scholar
• Harris VC, Armah G, Fuentes S, et al. Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana. J Infect Dis. 2017;215(1):34–41.
   PubMed Web of Science ®Google Scholar
• Cardemil CV, Estivariz C, Shrestha L, et al. The effect of diarrheal disease on bivalent oral polio vaccine (bOPV) immune response in infants in Nepal. Vaccine. 2016;34(22):2519–2526.
   PubMed Web of Science ®Google Scholar
• Emperador DM, Velasquez DE, Estivariz CF, et al. Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh. Clin Infect Dis. 2016;62(2):150–156.
   PubMed Web of Science ®Google Scholar
• Kazi AM, Cortese MM, Yu Y, et al. Secretor and Salivary ABO Blood Group Antigen Status Predict Rotavirus Vaccine Take in Infants. J Infect Dis. 2017;215(5):786–789.
   PubMed Web of Science ®Google Scholar
• Pollock L, Bennett A, Jere KC, et al. Nonsecretor Histo-blood Group Antigen Phenotype Is Associated With Reduced Risk of Clinical Rotavirus Vaccine Failure in Malawian Infants. Clin Infect Dis. 2019;69(8):1313–1319.
   PubMed Web of Science ®Google Scholar
• Armah GE, Cortese MM, Dennis FE, et al. Rotavirus Vaccine Take in Infants Is Associated With Secretor Status. J Infect Dis. 2019;219(5):746–749.
   PubMed Web of Science ®Google Scholar
• Vesikari T. Rotavirus vaccination: a concise review. Clin Microbiol Infect. 2012;18(Suppl 5):57–63.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370(9601):1757–1763.
   PubMed Web of Science ®Google Scholar
• Bibera GL, Chen J, Pereira P, et al. Dynamics of G2P[4] strain evolution and rotavirus vaccination: a review of evidence for Rotarix. Vaccine. 2020;38(35):5591–5600.
   PubMed Web of Science ®Google Scholar
• Leshem E, Lopman B, Glass R, et al. Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(9):847–856.
   PubMed Web of Science ®Google Scholar
• Burnett E, Parashar UD, Tate JE. Global Impact of Rotavirus Vaccination on Diarrhea Hospitalizations and Deaths Among Children <5 years old: 2006-2019. J Infect Dis. 2020;222(10):1731–1739.
   PubMed Web of Science ®Google Scholar
• Baker JM, Dahl RM, Cubilo J, et al. Effects of the rotavirus vaccine program across age groups in the United States: analysis of national claims data, 2001-2016. BMC Infect Dis. 2019;19(1):186.
   PubMedGoogle Scholar
• Bennett A, Pollock L, Bar-Zeev N, et al. Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study. Lancet Infect Dis. 2021;21(5):731–740.
   PubMed Web of Science ®Google Scholar
• Pollard SL, Malpica-Llanos T, Friberg IK, et al. Estimating the herd immunity effect of rotavirus vaccine. Vaccine. 2015;33(32):3795–3800.
   PubMed Web of Science ®Google Scholar
• Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9935):2136–2143.
   PubMed Web of Science ®Google Scholar
• Isanaka S, Guindo O, Langendorf C, et al. Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger. N Engl J Med. 2017;376(12):1121–1130.
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Desai S, Tewari T, et al. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35(45):6228–6237.
   PubMed Web of Science ®Google Scholar
• Naik SP, Zade JK, Sabale RN, et al. Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®). Vaccine. 2017;35(22):2962–2969.
   PubMed Web of Science ®Google Scholar
• Kawade A, Babji S, Kamath V, et al. Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants. Vaccine. 2019;37(19):2554–2560.
   PubMed Web of Science ®Google Scholar
• Chilengi R, Mwila-Kazimbaya K, Chirwa M, et al. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants. Vaccine. 2021;39(27):3633–3640.
   PubMed Web of Science ®Google Scholar
• Luan le T, Trang NV, Phuong NM, et al. Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam. Vaccine. 2009;27(Suppl 5):F130–8.
   PubMedGoogle Scholar
• Fu C, Wang M, Liang J, et al. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study. Vaccine. 2007;25(52):8756–8761.
   PubMed Web of Science ®Google Scholar
• Dang DA, Nguyen VT, Vu DT, et al. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine. 2012;30(Suppl 1):A114–21.
   PubMed Web of Science ®Google Scholar
• Anh DD, Carlos CC, Thiem DV, et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine. 2011;29(11):2029–2036.
   PubMed Web of Science ®Google Scholar
• Truong DTT, Kang JM, Tran NTH, et al. Rotavirus Genotype Trends from 2013 to 2018 and Vaccine Effectiveness in Southern Vietnam. Int J Infect Dis. 2021;105:277–285.
   PubMed Web of Science ®Google Scholar
• Patel M, Glass RI, Jiang B, et al. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis. 2013;208(2):284–294.
   PubMed Web of Science ®Google Scholar
• Angel J, Steele AD, Franco MA. Correlates of protection for rotavirus vaccines: possible alternative trial endpoints, opportunities, and challenges. Hum Vaccin Immunother. 2014;10(12):3659–3671.
   PubMed Web of Science ®Google Scholar
• Thiem VD, Anh DD, Ha VH, et al. Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants. Vaccine. 2021;39(32):4463–4470.
   PubMed Web of Science ®Google Scholar
• Fu C, Dong Z, Shen J, et al. Rotavirus Gastroenteritis Infection Among Children Vaccinated and Unvaccinated With Rotavirus Vaccine in Southern China: a Population-Based Assessment. JAMA Network Open. 2018;1(4):e181382.
   PubMed Web of Science ®Google Scholar
• Fu C, He Q, Xu J, et al. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine. 2012;31(1):154–158.
   PubMed Web of Science ®Google Scholar
• Fu C, Tate JE, Jiang B. Effectiveness of Lanzhou lamb rotavirus vaccine against hospitalized gastroenteritis: further analysis and update. Hum Vaccines. 2010;6(11):953.
   PubMed Web of Science ®Google Scholar
• Zhen SS, Li Y, Wang SM, et al. Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design. Emerg Microbes Infect. 2015;4(10):e64.
   PubMed Web of Science ®Google Scholar
• Xia S, Du J, Su J, et al. Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine. 2020;38(46):7393–7400.
   PubMed Web of Science ®Google Scholar
• Liu N, Xu Z, Li D, et al. Update on the disease burden and circulating strains of rotavirus in China: a systematic review and meta-analysis. Vaccine. 2014;32(35):4369–4375.
   PubMed Web of Science ®Google Scholar
• Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344(8):564–572.
   PubMed Web of Science ®Google Scholar
• Jiang J, Jiang B, Parashar U, et al. Childhood intussusception: a literature review. PloS One. 2013;8(7):e68482.
   PubMed Web of Science ®Google Scholar
• Soares-Weiser K, Bergman H, Henschke N, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2019;2019:10.
   Google Scholar
• Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33.
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22.
   PubMed Web of Science ®Google Scholar
• Clark A, Tate J, Parashar U, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. Lancet Glob Health. 2019;7(11):e1541–e52.
   PubMed Web of Science ®Google Scholar
• Yen C, Healy K, Tate JE, et al. Rotavirus vaccination and intussusception - Science, surveillance, and safety: a review of evidence and recommendations for future research priorities in low and middle income countries. Hum Vaccin Immunother. 2016;12(10):2580–2589.
   PubMed Web of Science ®Google Scholar
• Tate JE, Mwenda JM, Armah G, et al. Evaluation of Intussusception after Monovalent Rotavirus Vaccination in Africa. N Engl J Med. 2018;378(16):1521–1528.
   PubMed Web of Science ®Google Scholar
• Greenberg HB. Rotavirus vaccination and intussusception–act two. N Engl J Med. 2011;364(24):2354–2355.
   PubMed Web of Science ®Google Scholar
• INCLEN Intussusception Surveillance. Network Study Group. Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: a self-controlled case series analysis. Vaccine. 2021;39(1):78–84.
   PubMed Web of Science ®Google Scholar
• Reddy SN, Nair NP, Tate JE, et al. Intussusception after Rotavirus Vaccine Introduction in India. N Engl J Med. 2020;383(20):1932–1940.
   PubMed Web of Science ®Google Scholar
• Early Rollout of ROTAVAC®India Network. Assessment of risk of intussusception after pilot rollout of rotavirus vaccine in the Indian public health system. Vaccine. 2020;38(33):5241–5248.
   PubMed Web of Science ®Google Scholar
• Bines JE, At Thobari J, Satria CD, et al. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth. N Engl J Med. 2018;378(8):719–730.
   PubMed Web of Science ®Google Scholar
• Boniface K, Byars SG, Cowley D, et al. Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status. J Infect Dis. 2020;221(7):1070–1078.
   PubMed Web of Science ®Google Scholar
• At Thobari J, Damayanti W, Haposan JH, et al. Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: phase I Trial. Vaccine. 2021;39(33):4651–4658.
   PubMed Web of Science ®Google Scholar
• Hamidi A, Hoeksema F, Velthof P, et al. Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine. Vaccine. 2021;39(15):2048–2059.
   PubMed Web of Science ®Google Scholar
• Groome MJ, Fairlie L, Morrison J, et al. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2020;20(7):851–863.
   PubMed Web of Science ®Google Scholar
• Bines JE, Kotloff KL. Next-generation rotavirus vaccines: important progress but work still to be done. Lancet Infect Dis. 2020;20(7):762–764.
   PubMed Web of Science ®Google Scholar
• Groome MJ, Koen A, Fix A, et al. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017;17(8):843–853.
   PubMed Web of Science ®Google Scholar
• Vetter V, Gardner RC, Debrus S, et al. Established and new rotavirus vaccines: a comprehensive review for healthcare professionals. Hum Vaccin Immunother. 2021; Online ahead of print 1–17 https://doi.org/10.1080/21645515.2020.1870395
   Google Scholar
• Saluja T, Palkar S, Misra P, et al. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): randomized, controlled phase III study in Indian infants. Vaccine. 2017;35(28):3575–3581.
   PubMed Web of Science ®Google Scholar
• Luna EJ, Frazatti-Gallina NM, Timenetsky MC, et al. A phase I clinical trial of a new 5-valent rotavirus vaccine. Vaccine. 2013;31(7):1100–1105.
   PubMed Web of Science ®Google Scholar
• Kirkwood CD, Ma LF, Carey ME, et al. The rotavirus vaccine development pipeline. Vaccine. 2019;37(50):7328–7335.
   PubMed Web of Science ®Google Scholar
• Wu ZW, Li QL, Zhou HS, et al. Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine: a phase I clinical trial. Hum Vaccin Immunother. 2021;17(7):2311–2318.
   PubMed Web of Science ®Google Scholar
• Resch TK, Wang Y, Moon SS, et al. Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice. Sci Rep. 2018;8(1):561.
   PubMedGoogle Scholar
• Wang Y, Azevedo M, Saif LJ, et al. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine. 2010;28(33):5432–5436.
   PubMed Web of Science ®Google Scholar
• Jiang B, Wang Y, Glass RI. Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? Evidence from animal studies. Hum Vaccin Immunother. 2013;9(8):1634–1637.
   PubMed Web of Science ®Google Scholar
• Wang Y, Vlasova A, Velasquez DE, et al. Skin Vaccination against Rotavirus Using Microneedles: proof of Concept in Gnotobiotic Piglets. PloS One. 2016;11(11):e0166038.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zade J, Moon SS, et al. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species. Vaccine. 2019;37(5):698–704.
   PubMed Web of Science ®Google Scholar
• Lappalainen S, Pastor AR, Malm M, et al. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. Arch Virol. 2015;160(8):2075–2078.
   PubMed Web of Science ®Google Scholar
• Tamminen K, Lappalainen S, Huhti L, et al. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PloS One. 2013;8(7):e70409.
   PubMed Web of Science ®Google Scholar
• Ward RL, McNeal MM. VP6: a candidate rotavirus vaccine. J Infect Dis. 2010;202(Suppl):S101–7.
   PubMedGoogle Scholar
• Esteban LE, Temprana CF, Argüelles MH, et al. Antigenicity and immunogenicity of rotavirus VP6 protein expressed on the surface of Lactococcus lactis. Biomed Res Int. 2013;2013:298598.
   PubMed Web of Science ®Google Scholar
• Temprana CF, Argüelles MH, Gutierrez NM, et al. Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model. PloS One. 2018;13(9):e0203700.
   PubMed Web of Science ®Google Scholar
• Conner ME, Zarley CD, Hu B, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996;174(Suppl 1):S88–92.
   PubMedGoogle Scholar
• Tamminen K, Heinimäki S, Vesikari T, et al. VP6 Adjuvant Effect on Norovirus GII .4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo. J Immunol Res. 2020;2020:3194704.
   PubMed Web of Science ®Google Scholar
• Blazevic V, Malm M, Arinobu D, et al. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother. 2016;12(3):740–748.
   PubMed Web of Science ®Google Scholar
• Caddy SL, Vaysburd M, Wing M, et al. Intracellular neutralisation of rotavirus by VP6-specific IgG. PLoS Pathog. 2020;16(8):e1008732.
   PubMed Web of Science ®Google Scholar